2010
Does Switching to a New Antipsychotic Improve Outcomes? Data from the CATIE Trial
Rosenheck R, Davis S, Covell N, Essock S, Swart M, Stroup S, McEvoy J, Lieberman J. Does Switching to a New Antipsychotic Improve Outcomes? Data from the CATIE Trial. FOCUS The Journal Of Lifelong Learning In Psychiatry 2010, 8: 561-569. DOI: 10.1176/foc.8.4.foc561.Peer-Reviewed Original ResearchGreater weight gainNew medicationsOutcome measuresWeight gainNeurological side effectsAdditional outcome measuresPotential confounding factorsQuality of lifeStudy drugPrevious medicationCATIE trialMultivariate adjustmentImprove OutcomesMedicationsSide effectsOlanzapinePatientsConfounding factorsDrugsHealth costsOutcomesSignificant differencesRisperidoneCATIEMixed modelsExtrapyramidal side effects
Caroff S, Miller D, Rosenheck R. Extrapyramidal side effects. 2010, 156-172. DOI: 10.1017/cbo9780511712265.010.Peer-Reviewed Original ResearchAntipsychotic TrialsMental health policy makersExtrapyramidal side effectsDouble-blind conditionsClinical Antipsychotic TrialsIntervention Effectiveness (CATIE) projectHealth policy makersAntipsychotic medicationAntipsychotic drugsSide effectsKey treatmentComparative effectivenessMental healthSchizophreniaNational InstituteU.S. National InstituteMedicationsLandmark studiesPsychiatric researchersTrialsDrugsPharmaceutical companiesSpecific outcomesStatistical analysisClinicians
2009
Developing A Policy For Second-Generation Antipsychotic Drugs
Rosenheck RA, Sernyak MJ. Developing A Policy For Second-Generation Antipsychotic Drugs. Health Affairs 2009, 28: w782-w793. PMID: 19622538, DOI: 10.1377/hlthaff.28.5.w782.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychoticsAntipsychotic drugsRisk/benefit profileSecond-generation antipsychotic drugsMetabolic side effectsTreatment of schizophreniaAdverse eventsBenefit profileLower riskOld drugsSide effectsPrior authorizationDrugsCheaper drugsGeneric drugsEducational preparationWidespread implementationGood acceptanceSuch proceduresAntipsychoticsPatientsTherapySchizophrenia
2006
Special Section on CATIE Baseline Data: Components and Correlates of Family Burden in Schizophrenia
Perlick D, Rosenheck R, Kaczynski R, Swartz M, Cañive J, Lieberman J. Special Section on CATIE Baseline Data: Components and Correlates of Family Burden in Schizophrenia. Psychiatric Services 2006, 57: 1117-1125. PMID: 16870962, DOI: 10.1176/ps.2006.57.8.1117.Peer-Reviewed Original ResearchConceptsMedication side effectsQuality of lifeDaily livingService useSide effectsAcute inpatient phaseImpact of symptomsPatient problem behaviorsClinical Antipsychotic TrialsPatient's symptomsCaregiver burdenInpatient phaseAntipsychotic TrialsFamily burdenFamily caregiversCaregiver dataPatient behaviorTreatment programPatients' impairmentIncorporation of skillsSymptomsIntervention effectivenessDemographic characteristicsPrevious monthSchizophrenia
1998
Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Rosenheck R, Cramer J, Xu W, Grabowski J, Douyon R, Thomas J, Henderson W, Charney D. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Health Services Research 1998, 33: 1237-61. PMID: 9865219, PMCID: PMC1070315.Peer-Reviewed Original ResearchConceptsCost-effectiveness ratioRefractory schizophreniaVeterans Affairs Cooperative Study GroupHigh hospital usersIncremental cost-effectiveness ratioDouble-blind trialCooperative Study GroupDisease-specific measuresVA Medical CenterStandard assessment instrumentsMeasures of symptomsMultiple outcome domainsQuality Adjusted Life YearsComposite health indexAdjusted Life YearsHealth indexStudy entryPercent confidence intervalsAverage annual costStandard treatmentCost dataRole functioningStudy groupMedical CenterSide effectsPredictors of differential response to clozapine and haloperidol
Rosenheck R, Lawson W, Crayton J, Cramer J, Xu W, Thomas J, Stolar M, Charney D, Schizophrenia F. Predictors of differential response to clozapine and haloperidol. Biological Psychiatry 1998, 44: 475-482. PMID: 9777179, DOI: 10.1016/s0006-3223(98)00117-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAntipsychotic AgentsClozapineDouble-Blind MethodDrug ResistanceFemaleHaloperidolHumansMalePsychiatric Status Rating ScalesQuality of LifeRacial GroupsSchizophreniaSchizophrenic PsychologySocial SupportTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsQuality of lifeThree-month outcomeOnset of schizophreniaSeverity of symptomsGreater symptom reductionGreater improvementRefractory patientsRefractory schizophreniaClozapine treatmentHospital daysClinical predictorsExtrapyramidal symptomsHospitalized patientsClinical trialsBaseline predictorsSample patientsSide effectsSymptom reductionClozapinePatientsSymptomsHigher symptomsHigh levelsHaloperidolMultiple regression analysis
1997
A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia
Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D. A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia. New England Journal Of Medicine 1997, 337: 809-815. PMID: 9295240, DOI: 10.1056/nejm199709183371202.Peer-Reviewed Original ResearchConceptsClozapine groupExtrapyramidal side effectsHaloperidol groupRefractory schizophreniaSide effectsAntipsychotic drugsDouble-blind comparative studyVeterans Affairs Medical CenterMore outpatient servicesNegative Syndrome ScaleComparison of clozapineLower symptom levelsSimilar overall costsHospitalized patientsTreat analysisTardive dyskinesiaPsychiatric reasonsLower incidenceMedical CenterOutpatient servicesHospital usePatientsSyndrome ScaleClozapineHaloperidol